Jamal, Waheed

Cardiovascular and renal outcomes with empagliflozin in heart failure

Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine

Heart Failure Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 5,206

Empagliflozin in heart failure with a preserved ejection fraction

Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 4,874

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

Zannad, F., Ferreira, J. P., Pocock, S. J., Anker, S. D., Butler, J., Filippatos, G., Brueckmann, M., Ofstad, A. P., Pfarr, E., Jamal, W., et al. (2020) · The Lancet

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 1,408

Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial

Packer, M., Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Pocock, S. J., Carson, P., Anand, I., Doehner, W., Haass, M., et al. (2021) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 435

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial

Anker, S. D., Butler, J., Filippatos, G., Khan, M. S., Marx, N., Lam, C. S. P., Schnaidt, S., Ofstad, A. P., Brueckmann, M., Jamal, W., et al. (2021) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 352

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes

Abraham, W. T., Lindenfeld, J., Ponikowski, P., Agostoni, P., Butler, J., Desai, A. S., Filippatos, G., Gniot, J., Fu, M., Gullestad, L., et al. (2021) · European Heart Journal

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 217

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

Butler, J., Anker, S. D., Filippatos, G., Khan, M. S., Ferreira, J. P., Pocock, S. J., Giannetti, N., Januzzi, J. L., Piña, I. L., Lam, C. S. P., et al. (2021) · European Heart Journal

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 183

Empagliflozin and major renal outcomes in heart failure

Packer, M., Butler, J., Zannad, F., Pocock, S. J., Filippatos, G., Ferreira, J. P., Brueckmann, M., Jamal, W., Zeller, C., Wanner, C., et al. (2021) · New England Journal of Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 112